SCHEMBL18159675

SCHEMBL18159675

c1ccc(-n2c3ccccc3c3cc(-c4ccc5c(c4)c4cc(-c6ccc7c(c6)-c6ccccc6-c6ccccc6O7)ccc4n5-c4ccccc4)ccc32)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ ATM Q13315 2/20 0.47
▸ EDNRA P25101 5/20 0.36
▸ EDNRB P24530 1/20 0.36
▸ TSPO P30536 2/20 0.35
▸ PTGER4 P35408 1/20 0.34
▸ HDAC4 P56524 1/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ IL1R1 P14778 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ BRCA1 P38398 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ DNM1 Q05193 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16801298 1.00 L3MBTL1 (0.47) L3MBTL1KDM4EATMEDNRAEDNRB
SCHEMBL18159678 0.97 L3MBTL1 (0.45) L3MBTL1KDM4EATMEDNRAEDNRB
SCHEMBL16801213 0.97 L3MBTL1 (0.50) L3MBTL1KDM4EATMEDNRAEDNRB
SCHEMBL17485017 0.96 L3MBTL1 (0.46) L3MBTL1KDM4EATMEDNRAEDNRB
SCHEMBL16799960 0.95 L3MBTL1 (0.45) L3MBTL1KDM4EATMEDNRAEDNRB
SCHEMBL17485019 0.93 L3MBTL1 (0.43) L3MBTL1KDM4EATMEDNRAEDNRB
SCHEMBL17485018 0.93 L3MBTL1 (0.43) L3MBTL1KDM4EATMEDNRAEDNRB
SCHEMBL16801214 0.92 L3MBTL1 (0.47) L3MBTL1KDM4EATMEDNRAEDNRB
SCHEMBL21226922 0.92 L3MBTL1 (0.42) L3MBTL1KDM4EATMEDNRAEDNRB
SCHEMBL16801444 0.91 L3MBTL1 (0.43) L3MBTL1KDM4EATMEDNRAEDNRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11917913-B2 Substituted oxepines MERCK PATENT GMBH (DE) 2024-02-27 — — US disclosed
US-11917913-B2 Substituted oxepines MERCK PATENT GMBH (DE) 2024-02-27 — — US disclosed
EP-3649213-B1 COMPOSITION FOR ORGANIC ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2021-06-23 — — EP disclosed
US-20200216391-A1 COMPOSITION FOR ORGANIC ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2020-07-09 — — US disclosed
US-20190280218-A1 SUBSTITUTED OXEPINES MERCK PATENT GMBH (DE) 2019-09-12 — — US disclosed
US-10374170-B2 Substituted oxepines MERCK PATENT GMBH (DE) 2019-08-06 — — US disclosed
WO-2019007867-A1 COMPOSITION FOR ORGANIC ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2019-01-10 — — WO disclosed
US-20160308146-A1 SUBSTITUTED OXEPINES MERCK PATENT GMBH (DE) 2016-10-20 — — US disclosed
US-20160308146-A1 SUBSTITUTED OXEPINES MERCK PATENT GMBH (DE) 2016-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216391-A1 COMPOSITION FOR ORGANIC ELECTRONIC DEVICES SLCO2B1, SLCO4C1, SLCO2A1 L3MBTL1 3718/4885KDM4E 3376/4885ATM 4360/4885
US-11917913-B2 Substituted oxepines OXGR1, OXTR, OCIAD2 L3MBTL1 1480/4885KDM4E 710/4885ATM 1550/4885
US-10374170-B2 Substituted oxepines OXGR1, OXTR, OCIAD2 L3MBTL1 1480/4885KDM4E 710/4885ATM 1550/4885
US-20190280218-A1 SUBSTITUTED OXEPINES OXGR1, OXTR, OCIAD2 L3MBTL1 1480/4885KDM4E 710/4885ATM 1550/4885
US-20160308146-A1 SUBSTITUTED OXEPINES OXGR1, OXTR, OCIAD2 L3MBTL1 1480/4885KDM4E 710/4885ATM 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback